You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Monitored Breathing Awareness Therapy for Insomnia Disorder in Older Adults
SBC: ADVANCED MEDICAL ELECTRONICS CORP Topic: NIADESCRIPTION provided by applicant Insomnia of sufficient clinical severity to meet diagnostic criteria is present in approximately of older adults nearly million individuals n the US alone If left untreated it can lead to increased rates of depression cognitive impairment and cardiovascular disease Treatment relies on pharmacotherapy such as sedative hypnotic therapy which is ass ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Engineering stem cells to make mucopolysaccharidosis IIIB
SBC: Phoenix Nest Inc. Topic: 107DESCRIPTION provided by applicant Sanfilippo disease type B also called mucopolysaccharidosis type III or MPS III is a devastating neuro degenerative genetic disorder of childhood that is fatal There is no cure or effective treatment MPS IIIB is caused by the lack of a lysosomal enzyme called NAGLU alpha N acetylglucosaminidase that is required to degrade heparan sulfate glycosaminoglyca ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Human nasal epithelial organoids as a non-invasive, personalized model for predicting effectiveness of CFTR modulators in cystic fibrosis patients
SBC: Path BioAnalytics, Inc. Topic: ABCDESCRIPTION provided by applicant The discovery of the single gene CFTR cause of cystic fibrosis CF has been transformational focusing treatment on modulator drugs that restore function of the CFTR gene product CFTR andquot correctorsandquot enhance transport of mutant protein to the cell membrane and CFTR andquot potentiatesandquot activate mutant protein that does get to the membrane ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Reagents to Create Large DNA Constructs in One Assembly Step
SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC Topic: 100DESCRIPTION provided by applicant To many notably Craig Venter andquot synthetic biologyandquot means simply andquot synthesizing large amounts of DNAandquot This type of synthetic biology actually began in the andapos s when Caruthers introduced a phosphoramidite based solid phase DNA synthesis architecture This allowed ICI and the Benner group to synthesize complete genes encoding ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
CellRaft Array for Screening and Isolation of Highly Effective Cytotoxic T Cells
SBC: CELL MICROSYSTEMS INC Topic: NIAIDPROJECT SUMMARY Cell Microsystems Inc is an early stage biotechnology company whose mission is the commercialization of a novel cost effective platform enabling the identification and efficient isolation of viable cells based on morphologic and fluorescence signatures as well as characteristics that change over time The CellRaft technology is based on a unique cell array recently developed ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: NIAIDDESCRIPTION provided by applicant Our laboratory discovered and is developing partial p MHC class II constructs pMHC as a possible immunotherapy for multiple sclerosis MS pMHC containing the extracellular domains of the MS risk factor HLA DR linked covalently to the encephalitogenic peptide of myelin oligodendrocyte glycoprotein pDR MOG can reverse CNS inflammation and ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Multi-Channel Transmit- Multi-Channel Receive Coil Array for Human fMRI
SBC: LIFE SERVICES L.L.C. Topic: 101DESCRIPTION provided by applicant For this Phase I STTR proposal the investigators plan to develop the radiofrequency RF coil technology required for high resolution fMRI at T In the absence of a body transmit coil all T head coils must also incorporate a transmitter in addition to the receiver Here we propose a transmit array with up to individual channels combined with a receive a ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease
SBC: CoPlex Therapeutics, LLC Topic: NIAABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A Platform Technology for High-Throughput Screening of Gene Regulatory Elements
SBC: Element Genomics, Inc. Topic: 200Project Summary Abstract The goal of this proposal is to develop a novel high throughput platform for understanding gene regulatory elements in order to identify new drug targets for common diseases The human genome encodes approximately genes Understanding how those genes are regulated and how this correlates to complex cell phenotypes has long been a major focus of our team Follow up p ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A Bullet Proof vascular graft to prevent dialysis access cannulation injury
SBC: Innavasc Medical, Inc. Topic: 400Project Summary Abstract Synthetic arteriovenous grafts AVGs can provide life sustaining vascular access for dialysis patients but are subject to multiple modes of failure and complications related to chronic needle cannulation poor graft identification delayed access and bleeding These graft needle cannulation associated complications translate to millions of dollars in health care expense ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health